Depot medroxyprogesterone vs leuprorelin in endometriosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1532, 2006-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The anti-inflammatory action of danazol and leuprorelin acetate depot on endometriosis is CRH independent

By Matalliotakis Ioannis M.

Inflammopharmacology, Vol. 9, Iss. 3, 2001-06 ,pp. : 249-255

VSP

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Depot Leuprorelin

By Periti P. Mazzei T. Mini E.

Clinical Pharmacokinetics, Vol. 41, Iss. 7, 2002-01 ,pp. : 485-504

Adis International

Access to resources Recommend Favorite

Leuprorelin depot not inferior to chemo for nodal breast cancer

Inpharma, Vol. 1, Iss. 1595, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Medroxyprogesterone: Hyperglycaemia following depot injection in a woman with lipodystrophy: case report

Reactions Weekly, Vol. 1, Iss. 1215, 2008-01 ,pp. : 24-25

Adis International

Access to resources Recommend Favorite

Depot medroxyprogesterone increases risk of cardiovascular disease?

Inpharma, Vol. 1, Iss. 1355, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite